Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Trading Down 6.4% – Time to Sell?

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP)’s share price was down 6.4% during mid-day trading on Wednesday . The stock traded as low as $12.05 and last traded at $12.06. Approximately 28,775 shares were traded during trading, a decline of 32% from the average daily volume of 42,483 shares. The stock had previously closed at $12.88.

Analyst Ratings Changes

ARMP has been the topic of a number of analyst reports. HC Wainwright increased their price target on shares of Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. JonesTrading assumed coverage on shares of Armata Pharmaceuticals in a research note on Monday, January 5th. They issued a “buy” rating and a $15.00 target price for the company. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $15.00.

Armata Pharmaceuticals Price Performance

The company has a market cap of $421.25 million, a price-to-earnings ratio of -2.39 and a beta of 1.38. The stock has a 50-day moving average price of $10.03 and a 200 day moving average price of $7.29.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($3.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($3.23). The company had revenue of $1.09 million during the quarter, compared to analyst estimates of $0.74 million. Sell-side analysts expect that Armata Pharmaceuticals, Inc. will post -0.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Armata Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in Armata Pharmaceuticals during the 4th quarter worth about $108,000. Millennium Management LLC bought a new stake in shares of Armata Pharmaceuticals in the fourth quarter valued at about $164,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Armata Pharmaceuticals during the fourth quarter worth about $177,000. SeaCrest Wealth Management LLC grew its holdings in shares of Armata Pharmaceuticals by 17.3% during the fourth quarter. SeaCrest Wealth Management LLC now owns 40,988 shares of the company’s stock worth $274,000 after buying an additional 6,034 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in Armata Pharmaceuticals in the 4th quarter valued at approximately $284,000. 3.57% of the stock is owned by institutional investors.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.